Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics to Treat HSIL and Reduce Persistent High Risk HPV Infection in Women and Men Living With HIV
NCT06949800Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of EXE-346 in anal squamous intraepithelial lesion (ASIL), sponsored by University of California, San Francisco. Started Sep 2026; status: recruiting.
02
Drugs
EXE-346
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT06949800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949800.